Pharma Derivative

     SAN JOSE – While underplaying serious side-effects of its major trial drug, Omontys (peginesatide), directors of Affymax dumped $12 million of their shares before the price sank by 84 percent, knocking $524 million off its market cap, shareholders say in a derivative complaint in Santa Clara County Court.

%d bloggers like this: